Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
复制标题
DOI：
10.1038/s41598-017-11404-9
复制
发表时间：
2017-09-07
影响因子：
4.6
通讯作者：
Jiao S
中科院分区：
文献类型：
--
作者：
Chen Y;Li J;Chen S;Zhang Y;Hu Y;Zhang G;Yan X;Jiao S
白蛋白结合紫杉醇（nab-PC）和多西紫杉醇作为晚期非小细胞肺癌（NSCLC）的一线治疗均具有良好的疗效和安全性。然而，nab-PC与多西紫杉醇的比较目前尚不清楚。本回顾性研究旨在比较nab-PC/顺铂与多西他赛/顺铂作为一线治疗晚期NSCLC的疗效和安全性。本研究回顾了2012年至2016年接受nab-PC（55例）或多西他赛（216例）治疗的271例晚期NSCLC患者。主要终点为客观总有效率（ORR）。次要终点是疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和安全性。Nab-PC的ORR显著高于多西紫杉醇（47.3% vs 31.9%; P = 0.033）。鳞状组织患者的ORR差异更为显著（58.3% vs 29.0%; P = 0.007）。此外，nab-PC的DCR显著高于多西他赛。与多西他赛组相比，nab-PC组患者的PFS和OS均有改善的趋势，但差异无统计学意义。nab-PC组≥3级中性粒细胞减少较少，多西紫杉醇组≥3级贫血和血小板减少较少。Nab-PC/顺铂作为一线治疗晚期NSCLC的疗效明显高于多西紫杉醇/顺铂，且中性粒细胞减少明显减少。
Albumin-bound paclitaxel (nab-PC) and docetaxel both produced favorable efficacy and safety as first-line therapy in advanced non-small cell lung cancer (NSCLC). However, the comparison between nab-PC and docetaxel remained unclear until now. This retrospective study aimed to compare the efficacy and safety of nab-PC/cisplatin with docetaxel/cisplatin as first-line therapy in advanced NSCLC. 271 patients with advanced NSCLC, who received either nab-PC (55 patients) or docetaxel (216 patients) were reviewed from 2012 to 2016. The primary endpoint was objective overall response rate (ORR). The secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety profiles. Nab-PC presented a significantly higher ORR than docetaxel (47.3% vs 31.9%; P = 0.033). The difference of ORR was more significantly remarkable in patients with squamous histology (58.3% vs 29.0%; P = 0.007). Additionally, the DCR of nab-PC was significantly higher than docetaxel. Patients in nab-PC group had a trend toward improved PFS and OS compared with patients in docetaxel group, but this didn’t reach statistical significance. Grade ≥ 3 neutropenia was less in nab-PC group, while Grade ≥ 3 anemia and thrombocytopenia were less in docetaxel group. Nab-PC/cisplatin as first-line therapy, produced significantly higher efficacy and reduced neutropenia than docetaxel/cisplatin in advanced NSCLC.
登录
查看更多内容
影响因子：
6.2
作者：
Kottschade, Lisa A.;Suman, Vera J.;Amatruda, Thomas, III;McWilliams, Robert R.;Mattar, Bassam I.;Nikcevich, Daniel A.;Behrens, Robert;Fitch, Tom R.;Jaslowski, Anthony J.;Markovic, Svetomir N.
通讯作者：
Markovic, Svetomir N.
影响因子：
2.4
作者：
Koizumi W;Morita S;Sakata Y
通讯作者：
Sakata Y
影响因子：
2.3
作者：
Desai, Neil P.;Trieu, Vuong;Gradishar, William J.
通讯作者：
Gradishar, William J.
影响因子：
8.4
作者：
Le Chevalier, T;Monnier, A;Bérille, J
通讯作者：
Bérille, J
影响因子：
45.3
作者：
Fossella, F;Pereira, JR;Belani, CP
通讯作者：
Belani, CP